Vischer advised Mosanna Therapeutics in connection with its USD 80m Series A funding round. Headquartered in Basel, Switzerland, the clinical-stage biotech company, is working on a nighttime nasal spray to treat obstructive sleep apnea (OSA). The round EQT Life Sciences and Pivotal bioVenture Partners led the capital round in question, along with Forbion, Broadview Ventures […]
Baker McKenzie Switzerland – along with Baker McKenzie lawyers from the UK, US, Germany and further European jurisdictions – advised DocMorris on its rights offering with gross proceeds of CHF 208 million. In connection with the deal, Advestra
Pestalozzi advises a group of financial institutions representing a majority of holders of CHF 800 million in aggregate of convertible bonds issued by Idorsia, in connection with the holistic restructuring of the company. The context Headquartered
Homburger advised SIX Group AG on the issuance of EUR 500 m guaranteed bonds and CHF 250 m digital bonds.The two issuances took place respectively on 30 May 2025 and 4 June 2025, the first consisting in 500 m guaranteed bonds
Niederer Kraft Frey (NKF) represented the banking syndicate and Homburger advised consortium leader EQT on the sale of 8.0% of Galderma’s share capital via an accelerated bookbuilding process. The operation On May 27, 2025, a consortium led
Vischer advised GlycoEra in connection with its financing round. The Swiss biotechnology company, closed a USD 130 million Series B funding. BGPartner advised the lead investor Novo Holdings and new investor LifeArc Ventures on all Swiss
Homburger advised Avolta on its role in Dufry One’s issuance of EUR 500 m guaranteed notes. The operation On May 23, 2025, Dufry One issued EUR 500 m 4.50% senior notes, due 2032. Avolta guaranteed the issuance in question,
Homburger advised UBS on four different notes issuance operations starting February 2025. The issuances On February 10, 2025, UBS completed its offering of USD 1,500,000,000 in aggregate principal amount of 7.125% Tier 1 Capital Notes and USD 1,500,000,000 in aggregate principal amount
Niederer Kraft Frey (NKF) advised PolyPeptide Group on the securing of additional financing under its revolving credit facility, as well as further support from its main shareholder. In connection with the deal, Homburger advised UBS,
Swiss precision medicines company Haya Therapeutics completed a $65 million series A funding round. In connection with the deal, Kellerhals Carrard represented lead investors Sofinnova Partners and Earlybird Venture Capital, while Lenz & Staehelin assisted Eli
